Previous 10 | Next 10 |
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will presen...
2023-08-14 17:18:34 ET Spruce Biosciences press release ( NASDAQ: SPRB ): Q2 GAAP EPS of -$0.32. Revenue of $2.2M. For further details see: Spruce Biosciences GAAP EPS of -$0.32, revenue of $2.2M
Spruce Reports Interim Data from Phase 2 POWER Proof-of-Concept Study in Polycystic Ovary Syndrome (PCOS) CAHmelia Program in Adult Classic Congenital Adrenal Hyperplasia (CAH) Surpasses 75% Enrollment in CAHmelia-203 and Approaches 75% Enrollment in CAHmelia-204 Screening Underwa...
2023-06-23 13:04:00 ET Summary Shares of endocrine biopharma Spruce Biosciences, Inc. (SPRB) are off 80% from their IPO pricing, due mostly to a lack of catalysts since going public in 2020. That dynamic will change in 2H23, when the company will provide topline data from three tr...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for the 105 th Annual Meeting...
2023-06-09 17:15:14 ET Gainers: PepGen ( PEPG ) +5% . Caribou Biosciences ( CRBU ) +4% . MaxCyte ( MXCT ) +4% . Noodles & Company ( NDLS ) +3% . Applied Digital ( APLD ) +3% . Losers: Couchbase ( BASE ...
Accomplished life sciences industry executive brings more than 20 years of commercial and biopharmaceutical expertise to Spruce Board Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare e...
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will presen...
Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, accepted the Corporate Partner Award Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unm...
2023-05-16 17:23:00 ET Gainers: National Western Life Group ( NWLI ) +17% . Extreme Networks ( EXTR ) +7% . Lyell Immunopharma ( LYEL ) +5% . PacWest Bancorp ( PACW ) +5% . Spruce Biosciences ( SPRB ) +5% . Losers: EVgo...
News, Short Squeeze, Breakout and More Instantly...
Spruce Biosciences Inc. Company Name:
SPRB Stock Symbol:
NASDAQ Market:
Spruce Biosciences Inc. Website:
Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, announced that the San Francisco Business Times and the Silicon Valley Busines...
Pairs Spruce’s Investigational Product Candidate, Tildacerfont, with HMNC’s Companion Diagnostic, the Proprietary Cortibon Genetic Selection Tool, to Treat MDD Patients Responsive to CRF 1 Receptor Antagonism Provides Spruce with Option to In-License Exclusive Worldwide ...
Significant Reduction in Dehydroepiandrosterone Sulfate ( DHEAS) Versus Placebo Observed in Women with Elevated DHEAS Levels at Baseline Increase in Serum Sex Hormone Binding Globulin (SHBG) Versus Placebo Observed Tildacerfont was Well-Tolerated with No Safety Signals ...